FibroBiologics Inc. (NASDAQ:FBLG) Short Interest Up 100.7% in May

FibroBiologics Inc. (NASDAQ:FBLG) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totaling 237,640 shares, an increase of 100.7% from the April 30th total of 118,414 shares. Currently, 5.0% of the company’s shares are sold short. Based on an average trading volume of 563,635 shares, the days-to-cover ratio is currently 0.4 days.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $8.00 price objective (up from $4.00) on shares of FibroBiologics in a report on Thursday, April 16th. Wall Street Zen upgraded shares of FibroBiologics to a “sell” rating in a report on Saturday, April 4th. Maxim Group lowered shares of FibroBiologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. D. Boral Capital restated a “hold” rating on shares of FibroBiologics in a report on Thursday, March 26th. Finally, Weiss Ratings lowered shares of FibroBiologics from a “sell (e+)” rating to a “sell (e)” rating in a report on Monday. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $74.00.

FibroBiologics Stock Down 6.3%

NASDAQ:FBLG opened at $1.05 on Wednesday. The company has a fifty day moving average of $1.72 and a 200 day moving average of $4.49. FibroBiologics has a 52 week low of $0.95 and a 52 week high of $19.80. The firm has a market capitalization of $5.47 million, a P/E ratio of -0.15 and a beta of 1.13.

FibroBiologics (NASDAQ:FBLG) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($1.33) EPS for the quarter, meeting analysts’ consensus estimates of ($1.33). As a group, analysts anticipate that FibroBiologics will post -4.41 EPS for the current year.

Institutional Investors Weigh In On FibroBiologics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FBLG. AQR Capital Management LLC bought a new stake in FibroBiologics during the 1st quarter valued at $29,000. XTX Topco Ltd raised its holdings in FibroBiologics by 160.0% during the 2nd quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock valued at $29,000 after buying an additional 28,276 shares during the last quarter. Marshall Wace LLP bought a new stake in FibroBiologics during the 2nd quarter valued at $49,000. Cerity Partners LLC raised its holdings in FibroBiologics by 37.2% during the 2nd quarter. Cerity Partners LLC now owns 128,109 shares of the company’s stock valued at $80,000 after buying an additional 34,702 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in FibroBiologics during the 2nd quarter valued at $60,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.